Henry McCusker's  Instablog

Henry McCusker
Send Message
Analyst, Journalist and Publisher ... Henry enters his tenth (10) year at Scimitar Equity -Regenerative Medicine Investors which aggregates, curates and creates bottom-line content weeding of regenerative medicine and cell therapy news to provide a customized, vetted selection of relevant and... More
My company:
Scimitar Equity-Regenerative Medicine Investors
My blog:
Scimitar Equity Blog
  • Updating,ThermoGenesis (KOOLD) 4 comments
    Sep 24, 2010 1:58 PM

    KOOLD reported a Q4/10 net loss of $171,000, or $0.01 per share compared to a net loss of $1.4 M, or $0.10 per share in Q3/10. KOOLD reported a net loss of $5.2 M, or $0.37 per share, in FY10 versus a net loss of $8.6 M or $0.61 per share in FY09.

    Q/4/10 revenues were $7.2 M which disposable revenues of $4.8 M. The per share results for all periods had been adjusted to reflect the impact of the reverse stock split that occurred at the close of business on 8/26/10. KOOLD ended FY10 with $10.7 M in cash and short-term investments versus $10.1 M at the end of Q3/10 and $15.6 M at the end of FY09.

    • For FY10, KOOLD reported revenues of $23.1 M, an increase of 17% versus revenues of $19.8 M in FY09;
    • Disposable revenues for FY10 were $14.3 M versus disposable revenues of $10.6 M in FY09, an increase of 35%.

    KOOLD ended Q4/10 highlighted a 78% increase over revenues from Q3/09  with strong sales of  AXP® AutoXpress™ (NYSE:AXP) System bag sets and  BioArchive® Systems.

    • This revenue growth, combined with successes at managing operating expenses, enabled reduction of net loss quarter-over quarter by approximately $3 M and achieve near break even;
    • Results for FY10 reflect a  39% reduction in their net loss year-over-year;
    •  KOOLD realized meaningful improvement in gross margins as disposable revenues were 62% of total revenues versus 54% a year ago;
    • In Q1/11, KOOLD will record 2 non-recurring charges. These charges are expected to total approximately $200,000 and include the severance and restructuring costs associated with our 7/1/10 lay-off and an early termination fee for a facility lease being vacated.
Back To Henry McCusker's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (4)
Track new comments
  • James Levy
    , contributor
    Comments (82) | Send Message
    Thanks for this update on what I believe is an excellent microcap opportunity. I recently published a instablog on Thermogenesis as well, fully expecting that it would be published as an article. However, the editors at Seeking Alpha rejected it. When I appealed their decision, they gave me reasons which were not all convincing, including that ¨the share had changed symbols¨(duh!!, reverse split) and there had been ¨problems with the NASDAQ listing ¨(since resolved by reverse split). Anyway, I post a link to my blog which I hope you and your readers will find useful:


    25 Sep 2010, 04:17 AM Reply Like
  • yellowtailcheek
    , contributor
    Comments (55) | Send Message
    james, you are already up 60% on kool's prediction ... good job.


    i see kool has many more up-legs coming, the current management is absolutely capable of making kool a very profitable company.


    thank you for your work.
    17 Oct 2010, 06:34 PM Reply Like
  • James Levy
    , contributor
    Comments (82) | Send Message
    Thanks yellowtailcheek, it is a great feeling to get positive feedback. I´m holding on to Thermogenesis (KOOL). Lately been entering PSDA and SNTS as well, might write about them, but am discouraged by Seeking Alpha´s refusal to publish my KOOL article (60% lower price than today!)
    21 Oct 2010, 05:55 AM Reply Like
  • yellowtailcheek
    , contributor
    Comments (55) | Send Message
    I can't find PSDA and I think SNTS has too many shares out there that attract low quality investors( aka day-traders).


    You need to pay attention to KOOL's recent development especially it's Res-Q line of business, it goes into bone marrow and PRP areas of the market especially the PRP in sports medicine and cardio therapy aside from the major applications in general surgery and wound healing.
    23 Oct 2010, 09:19 PM Reply Like
Full index of posts »
Latest Followers


  • ImmunoCellular (OTC BB: IMUC) files to Sell $13.8M of Units via Cowen
    Nov 30, 2011
  • Mid-Day Movers: BioTime (AMEX: BTX), Cytori (CYTX), Geron (GERN), Neuralstem (AMEX: CUR), ReNeuron (RENE.LON), ThermoGenesis (KOOL)
    Oct 26, 2011
More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.